Sodium-glucose co-transporter 2 (SGLT2) inhibitors block glucose reabsorption in the renal
proximal tubule, an insulin-independent mechanism that plays a critical role in glycemic …

Purpose of review SGLT2 inhibitors (SGLT2i) are new drugs for patients with heart failure
(HF) irrespective of diabetes. However, the mechanisms of SGLT2i in HF remain elusive …

Aims To examine the effects of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on
cardiac remodelling in patients with type 2 diabetes mellitus (T2DM) and/or heart failure …

The prevalence of kidney disease is increasing rapidly worldwide, reflecting rising rates of
obesity, diabetes, and associated metabolic syndrome (MetS). Chronic kidney disease and …

Hypertensive heart disease (HHD) is currently the second leading cause of heart failure. The
prevalence of HHD and its associated risk of heart failure have increased despite substantial …

Vascular aging, early vascular aging or supernormal vascular aging are concepts used for
estimating the cardiovascular risk at a certain age. From the famous line of Thomas …

Hypertension is one of the most important causes of mortality, affecting the health status of
the patient. At the same time, hypertension causes a huge health and economic burden on …

Background Prior research suggests clinical effects of glucagon‐like peptide‐1 receptor
agonists (GLP‐1RAs) and sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) are …

Objectives Heart failure with mildly reduced ejection fraction (HFmrEF) or heart failure with
preserved ejection fraction (HFpEF) are associated with significant morbidity and mortality …

Background: Avoidable disparities in health outcomes persist in Canada despite substantial
investments in a publicly funded health care system that includes preventive services. Our …